ClinicalTrials.gg
RecruitingNCT07356323Updated Nov 13, 2026

A Prospective, Single-arm, Trial to Determine Contamination Rates When Using an Antibacterial Incise Drape During Orthopedic Surgery

An interventional study of 3M™ Ioban™ CHG Chlorhexidine Gluconate Incise Drape (2% w/w CHG) in Arthroplasty Replacement, Knee and Arthroplasty Total Hip Replacement, sponsored by Solventum US LLC. Recruiting at 2 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Solventum US LLC · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Updated Nov 13, 2026Site recruiting status changedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
179
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Study summary

The goal of this clinical study is to generate data on the intended use of a chlorhexidine gluconate (CHG)-impregnated antimicrobial incise drape. The study includes subjects undergoing primary hip or knee arthroplasty procedures.

The study evaluates the intraoperative performance and safety of the incise drape during surgery, including assessment of contamination and operative characteristics.

Participants will have a CHG-impregnated antimicrobial incise drape applied during their surgical procedure. During surgery, samples will be collected from the operative site to assess potential bacterial contamination.

Read the detailed description

This is a prospective, single-arm clinical study conducted in the United States in subjects undergoing primary hip or knee arthroplasty. The study evaluates the intraoperative performance and safety of a chlorhexidine gluconate (CHG)-impregnated antimicrobial incise drape used during lower extremity orthopedic surgery.

Safety and intraoperative performance outcomes will be assessed throughout the study.

02

Conditions studied

  • Arthroplasty Replacement, Knee
  • Arthroplasty Total Hip Replacement

Keywords

  • Chlorohexidine Gluconate
  • Incise drape
  • CHG
  • Ioban
03

In context

Lead sponsor

Solventum US LLC is the lead sponsor of 64 studies on the registry; 2 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is ≥ 22 years of age on the day of surgery.
  • Subject is scheduled to undergo a unilateral primary arthroplasty procedure on a hip or knee.
  • Subject is capable of providing .
  • Subject is willing and able to return for all visits.

Exclusion criteria

Exclusion Criteria:

  • Subject is pregnant or lactating prior to surgery.*

    *Women who have had surgical sterilization by a medically accepted method (e.g., tubal ligation, hysterectomy, or oophorectomy) or are , defined as not having menstruation for > 12 months will not be required to undergo pregnancy testing

  • Subject is scheduled to undergo a lower extremity bilateral arthroplasty procedure.
  • Subject had a previous open knee surgery on the study knee or is scheduled to undergo a revision knee arthroplasty.
  • Subject has had a previous surgery for revision femoral acetabular osteotomy or total hip arthroplasty on the study hip.
  • Subject is scheduled for lower extremity arthroplasty due to trauma.
  • Subject was previously diagnosed with septic arthritis or has a history of infection in the joint.
  • Subject has taken any antibiotics within 4 weeks before surgery.
  • Subject has an allergy or sensitivity to components of the device (e.g., chlorhexidine gluconate or acrylate-based adhesive).
  • Subject is currently enrolled in another trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
179 participants (estimated)

Study arms

  • Experimental
    Single Treatment Arm

    Subjects undergoing primary hip or knee arthroplasty will have a chlorhexidine gluconate (CHG)-impregnated antimicrobial incise drape applied to the surgical site prior to incision and maintained in place for the duration of the surgical procedure.

    Device: 3M™ Ioban™ CHG Chlorhexidine Gluconate Incise Drape (2% w/w CHG)

Interventions

  • Device3M™ Ioban™ CHG Chlorhexidine Gluconate Incise Drape (2% w/w CHG)

    A CHG-impregnated antimicrobial incise drape applied to the surgical site prior to incision during primary hip or knee arthroplasty.

06

What researchers measure

Primary outcomes

  1. Evaluation of the presence of contamination at the surgical site during the operative procedure.

    Assessment of contamination at the surgical site during the operative procedure.

    Time frame: During surgery

Other outcomes

  1. Percentage of Subjects With Loss of Incise Drape Adherence Greater Than 10 mm During Surgery

    The percentage of subjects who experience loss of adherence of the incise drape of more than 10 millimeters (mm) at the incision site during the surgical procedure.

    Time frame: During surgery

  2. Operative Time

    Operative time measured in minutes

    Time frame: During surgery

07

Study locations

1 of 2 sites recruiting
  • Indiana University Health (IU Health)
    Fishers, Indiana 46037, United States
    Completed

    Not enrolling at this site.

  • University of Utah Health - Department of Orthopedics
    Salt Lake City, Utah 84108, United States
    Recruiting
    • Jeremy Gililland, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2026 (actual). Primary completion is estimated for Nov 2026, 9 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Sep 2026 → Nov 2026 and completion Oct 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2026
First posted
Jan 21, 2026
StartActual
Feb 19, 2026
Primary completionEst.
Nov 20, 2026was Sep 2026
CompletionEst.
Nov 20, 2026was Oct 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Indiana University Health (IU Health) is now Completed
Nov 13, 2026
Primary completion
Sep 4, 2026→Nov 20, 2026
Nov 13, 2026
Study completion
Oct 2026→Nov 20, 2026
Nov 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Indiana University Health (IU Health) · Fishers, United StatesContact removed (no phone or email listed)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Indiana University Health (IU Health) is now Completed
    Primary completion Sep 4, 2026→Nov 20, 2026
    Study completion Oct 2026→Nov 20, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Indiana University Health (IU Health) · Fishers, United StatesContact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07356323
Lead sponsor
Solventum US LLC
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Feb 19, 2026
Primary completion
Nov 20, 2026 (estimated)
Completion
Nov 20, 2026 (estimated)
Last update
Nov 13, 2026

Study contacts

Tracy E Swanson
Contact
tswanson@solventum.com
6125417752
Stephanie Karwedsky
Contact
skarwedsky@solventum.com
6124272830

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion